Krankenhaus Nordwest

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Gastric and oesophageal cancer5 trials
• Colorectal cancer1 trial
• Lung cancer1 trial
• Metastatic breast cancer1 trial
• Neuroendocrine tumours1 trial
• Pancreatic cancer1 trial

Phase

• Phase 23 trials
• Phase 1/21 trial
• Phase 2/31 trial
• Phase 31 trial
• Phase 41 trial

Status

• Completed4 trials
• Active, not recruiting2 trials
• Not yet recruiting1 trial
• Recruiting1 trial
• Terminated1 trial

Lead sponsor

• Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest4 trials
• Ipsen2 trials
• BioInvent International AB1 trial
• Cardiovascular and Interventional Radiological Society of Europe1 trial
• Nikolaj Frost MD1 trial

Running trials

• Recruiting

  Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

  NCT07176312· Phase 2· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

  Contact: Thorsten Götze, Prof. Dr.

• Recruiting

  Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

  NCT07314164· Ipsen· Source

  Contact: Ipsen Clinical Study Enquiries

• Active, not recruiting

  Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma

  NCT05689671· Phase 4· Nikolaj Frost MD· Source

• Active, not recruiting

  Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness

  NCT03421288· Phase 2· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Gastric and oesophageal cancer1 recruiting
• Neuroendocrine tumours1 recruiting

Closed trials

• Terminated

  BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors

  NCT05555251· Phase 1/2· BioInvent International AB· Source

• Completed

  A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

  NCT04083235· Phase 3· Ipsen· Source

• Completed

  CIRSE Emprint Microwave Ablation Registry

  NCT03775980· Cardiovascular and Interventional Radiological Society of Europe· Source

• Completed

  Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

  NCT03647969· Phase 2· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy

  NCT03081143· Phase 2/3· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source